References
- American Foundation for AIDS Research (amfAR) . 2005 , April ). Survey results . Presented at the 17th National HIV/AIDS Update Conference, Oakland, CA. Retrieved September 2, 2008, from http://www.amfar.org/cgi-bin/iowa/programs/researchc/record.html?record=232
- Arasteh , K. Lazzarin , A. , Clotet , B. , Lalezari , J. , Cooper , D. , Henry , K. , et al. . 2004 . TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen . XV International AIDS Conference, July, Bangkok; Abstract MoOrB1058 .
- Campbell , C. and McGauley , G. 2005 . Doctor-patient relationships in chronic illness: Insights from forensic psychiatry . British Medical Journal , 330 : 667 – 670 .
- Cohen , C.J. , Hellinger , J. , Johnson , M. , Staszewski , S. , Wintfeld , N. Patel , K. 2003 . Patient acceptance of self-injected enfuvirtide at 8- and 24-weeks . HIV Clinical Trials , 4 : 347 – 357 .
- Eron , J. , Delfraissy , J.F. , Kuritzkes , D. , Stellbrink , H.-J. , Cohenn , C. , DeMasi , R. , et al. . 2003 . Safety of enfuvirtide through 48 weeks of therapy in the TORO trials . 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September. Chicago; Abstract H-836 .
- Greenberg , M.L. , Sista , P. , & Miralles , G. 2002 Enfuvirtide (T-20) and T-1249 resistance: Observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals (ARVs) and a Phase I/II doseranging monotherapy trial of T-1249 . XI International HIV Drug Resistance Workshop, July. Seville .
- Horne , R. , Coombes , I. , Davies , G. , Hankins , M. and Vincent , R. 1999 . Barriers to optimum management of heart failure by general practitioners . British Journal of General Practice , 49 : 353 – 357 .
- Katlama , C. , Arastéh , K. , Clotet , B. , Cooper , D. , Henry , K. , Lalezari , J. , et al. . 2003 . Enfuvirtide TORO studies: 48-week results confirm 24-week findings . 2nd International AIDS Society Meeting, July, Paris; Abstract LB2 .
- Lalezari , J.P. , Henry , K. , O'Hearn , M. , Montaner , J.S. , Piliero , P.J. Trottier , B. 2003 . Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America . New England Journal of Medicine , 348 : 2175 – 2185 .
- Lazzarin , A. , Clotet , B. , Cooper , D. , Reynes , J. , Arastéh , K. Nelson , M. 2003 . Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia . New England Journal of Medicine , 348 : 2186 – 2195 .
- Montaner , J. , et al. . 2004 . A treatment staging proposal derived from a post-hoc analysis of the 48-week results from the TORO studies . 15th International AIDS Conference, July, Bangkok; Abstract TuPEB4483 .
- Perry , N. , et al. . 2005 . T20 Use in the UK: Is it Optimal? 11th Annual Conference of the British HIV Association [BHIVA] with the British Association for Sexual Health and HIV [BASHH]. Dublin, Ireland, 21–23 April; Abstract P31
- Trottier , B. , Arastéh , K. , Henry , K. , Katlama , C. , Lazarin , A. , Montaner , J. , et al. . 2004 Durability of response of enfuvirtide through 48 weeks in the TORO trials . 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September. Chicago; Abstract H-835 .